Ashutosh K Pathak - JoVE Visualize

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Journal of the American College of Nutrition|January 27, 2005

Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancerAshutosh K Pathak, Manisha Bhutani, Randeep Guleria, et al.

Lung Cancer (Amsterdam, Netherlands)|July 6, 2014

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancerCorey J Langer, Istvan Albert, Helen J Ross, et al.

European Journal of Cancer (Oxford, England : 1990)|March 16, 2013

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.

Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Journal of the American College of Nutrition|January 27, 2005

Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancerAshutosh K Pathak, Manisha Bhutani, Randeep Guleria, et al.

Lung Cancer (Amsterdam, Netherlands)|July 6, 2014

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancerCorey J Langer, Istvan Albert, Helen J Ross, et al.

European Journal of Cancer (Oxford, England : 1990)|March 16, 2013

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.

Pageof 4